Mary Wilson
Well-known member
14 September 2024 | Emergency Situational Updates
Highlights
• On 14 August 2024, the WHO Director-General declared the resurgence of mpox to be a public health
emergency of international concern (PHEIC), requiring a coordinated international response.
• This report focuses on the reporting period 1 January – 8 September 2024, as the latest complete
epidemiological week, for the African continent. Global updates will be included once a month.
• The number of suspected and confirmed mpox cases reported in Africa in 2024 continues to increase.
The most affected countries currently are the Democratic Republic of the Congo and Burundi.
• Testing coverage in the Democratic Republic of the Congo remains low, due to limited testing capacity,
and the number of suspected cases is around five times the number of laboratory-confirmed ones.
• Mpox case fatality ratio in the Democratic Republic of the Congo in 2024 is 0.5% among confirmed cases
(25 deaths out of 5160 cases) and 3.3% among suspected cases (717 deaths among 21 835 cases).
• In Africa, the two monkeypox virus (MPXV) clades and their subclades circulate in different geographic
areas and affecting different populations, therefore need tailored and locally-adapted outbreak
responses.
• Clade Ib, in circulation for approximately one year, has been associated with sustained human-to-human
transmission and a rising trend in reported cases in eastern Democratic Republic of the Congo. Clade
Ib is also causing an ongoing outbreak in Burundi.
• Although genomic sequencing capacity is limited, clade Ib appears to be the predominant strain in the
North and South Kivu provinces of the Democratic Republic of the Congo, Burundi, Rwanda, Kenya, and
Uganda, and has been confirmed in imported cases in Sweden and Thailand, one case in each county.
• This report presents an overview of the epidemiological situation in three countries that have national
declarations of mpox outbreaks (Democratic Republic of the Congo, Burundi and Central African
Republic). Future reports will include overviews from more countries.
• Comprehensive global, continental and national planning to address the mpox situation are underway.
This report provides an overview of WHO global mpox response activities.
• This report also includes two brief special focus sections providing updates on laboratory testing for
clade Ib MPXV and the current global situation regarding vaccine availability and distribution.
• WHO has announced on 13 September the prequalification of MVA-BN vaccine, the first vaccine against
mpox to be prequalified.
In this edition:
• Situation overview
• Epidemiological update
• Global situation
• Situation in Africa
• Monkeypox virus distribution in Africa
• Epidemiological focus on selected countries
• Global operational updates
• Special Focus
• Laboratory testing for MPXV
• WHO mpox resources
Situation overview ...
https://cdn.who.int/media/docs/defa...d13af8c8b.pdf?sfvrsn=5795b34c_1&download=true
Highlights
• On 14 August 2024, the WHO Director-General declared the resurgence of mpox to be a public health
emergency of international concern (PHEIC), requiring a coordinated international response.
• This report focuses on the reporting period 1 January – 8 September 2024, as the latest complete
epidemiological week, for the African continent. Global updates will be included once a month.
• The number of suspected and confirmed mpox cases reported in Africa in 2024 continues to increase.
The most affected countries currently are the Democratic Republic of the Congo and Burundi.
• Testing coverage in the Democratic Republic of the Congo remains low, due to limited testing capacity,
and the number of suspected cases is around five times the number of laboratory-confirmed ones.
• Mpox case fatality ratio in the Democratic Republic of the Congo in 2024 is 0.5% among confirmed cases
(25 deaths out of 5160 cases) and 3.3% among suspected cases (717 deaths among 21 835 cases).
• In Africa, the two monkeypox virus (MPXV) clades and their subclades circulate in different geographic
areas and affecting different populations, therefore need tailored and locally-adapted outbreak
responses.
• Clade Ib, in circulation for approximately one year, has been associated with sustained human-to-human
transmission and a rising trend in reported cases in eastern Democratic Republic of the Congo. Clade
Ib is also causing an ongoing outbreak in Burundi.
• Although genomic sequencing capacity is limited, clade Ib appears to be the predominant strain in the
North and South Kivu provinces of the Democratic Republic of the Congo, Burundi, Rwanda, Kenya, and
Uganda, and has been confirmed in imported cases in Sweden and Thailand, one case in each county.
• This report presents an overview of the epidemiological situation in three countries that have national
declarations of mpox outbreaks (Democratic Republic of the Congo, Burundi and Central African
Republic). Future reports will include overviews from more countries.
• Comprehensive global, continental and national planning to address the mpox situation are underway.
This report provides an overview of WHO global mpox response activities.
• This report also includes two brief special focus sections providing updates on laboratory testing for
clade Ib MPXV and the current global situation regarding vaccine availability and distribution.
• WHO has announced on 13 September the prequalification of MVA-BN vaccine, the first vaccine against
mpox to be prequalified.
In this edition:
• Situation overview
• Epidemiological update
• Global situation
• Situation in Africa
• Monkeypox virus distribution in Africa
• Epidemiological focus on selected countries
• Global operational updates
• Special Focus
• Laboratory testing for MPXV
• WHO mpox resources
Situation overview ...
https://cdn.who.int/media/docs/defa...d13af8c8b.pdf?sfvrsn=5795b34c_1&download=true